Xtract.io’s Pharmacy & Drug Store Location Data provides a complete geospatial view of pharmaceutical retail across the United States and Canada. This dataset includes handcrafted polygons and geocoded coordinates for each pharmacy location, making it a powerful resource for healthcare planners, market researchers, and retail strategists.

Organizations can leverage this dataset to:

• Conduct healthcare accessibility mapping and identify underserved areas.

• Evaluate market penetration and retail coverage across regions.

• Analyze the competitive landscape in pharmaceutical retail.

• Support site selection and expansion strategies.

How We Build Pharmacy Polygons

• Manually crafted polygons created using GIS tools like QGIS and ArcGIS, with aerial and street-level imagery.

• Integration of venue layouts and elevation plans from official sources for enhanced accuracy.

• Rigorous multi-stage quality checks ensure accuracy, completeness, and relevance.

What Else We Offer

• Custom polygon creation for any retail chain, healthcare facility, or point of interest.

• Enhanced metadata including entry/exit points, parking areas, and surrounding context.

• Flexible formats: WKT, GeoJSON, Shapefile, and GDB for smooth system integration.

• Regular updates tailored to client needs (30, 60, 90 days).

• Unlock the Power of Healthcare Geospatial Data

With detailed pharmacy polygon data and POI datasets, businesses can:

• Map healthcare service coverage and accessibility.

• Identify growth opportunities in underserved communities.

• Decode consumer behavior in the pharmaceutical retail space.

• Strengthen location-driven strategies with spatial intelligence.

Why Choose LocationsXYZ?

LocationsXYZ is trusted by enterprises worldwide to deliver 95% accurate, handcrafted POI and polygon data. With our pharma dataset, you gain actionable insights to support healthcare planning, retail expansion, and competitive benchmarking.

The Electronic Health Records Market size was valued at USD 29.06 billion in 2023 and is projected to reach USD 38.50 billion by 2032, exhibiting a CAGR of 4.1 % during the forecasts period. Recent developments include: In July 2023, NextGen Healthcare announced the expansion of its collaboration with the American Podiatric Medical Association (APMA). As per this collaboration, the ‘NextGen Office’ cloud-based small practice EHR and practice management solution is the sole platform to incorporate blueprints exclusively developed with APMA. These podiatry blueprints address several issues, including diabetes, dermatitis, infection, and injuries. , In June 2023, CPSI and the MidCoast Health System expanded their four-year partnership, through the implementation of CPSI’s EHR, accounts receivables services, and IT-managed services at the ‘Crockett Medical Center’ critical access hospital in Texas. Other MidCoast Health System hospitals to successfully implement CPSI healthcare solutions in recent years include the El Campo Memorial Hospital and the Palacios Community Medical Center, among others. , In May 2023, MEDITECH announced an agreement with Canada Health Infoway to connect with the latter’s e-prescribing service ‘PrescribeIT’. This agreement would allow prescribers in Canada to electronically transmit a prescription directly from MEDITECH’s Expanse EHR to the patient’s preferred choice of pharmacy. The functionality would allow ease of creation of new prescriptions, allow existing prescription renewal, and also cancel prescription requests. , In April 2023, Microsoft announced an expansion of its strategic partnership with Epic for the development and integration of generative AI into healthcare, through the combination of Epic’s advanced electronic health record software and the scale of Microsoft’s Azure OpenAI Service. The resulting generative AI solutions would help enhance patient care, increase productivity, and improve the financial integrity of health systems worldwide. , In February 2023, King’s College Hospital London - Dubai announced a strategic partnership with Oracle Cerner to accelerate innovation, through the utilization of Oracle Cloud Infrastructure (OCI) services via the Oracle Cloud Dubai Region for operating and managing the upgraded and enhanced electronic medical records system for KCH Dubai. , In February 2023, Oracle Cerner announced that the province of Nova Scotia, in partnership with Nova Scotia Health Authority (NSHA) and IWK Health (IWK), had signed a 10-year agreement for implementing an integrated electronic care record in the entire province. Known in Nova Scotia as “One Person One Record”, it is intended to provide clinicians easier access to real-time health information and allow healthcare workers to spend more time with their patients. , In January 2023, Veradigm (formerly Allscripts) announced that the Veradigm Network EHR Data would be available within the OMOP CDM format. Veradigm Network EHR is a complete statistically de-identified dataset with three integrated EHR sources. This transformation is expected to facilitate data sales for clients who require it to be delivered in OMOP format. , In January 2022, Health Information Management Systems, launched AxiaGram, a mobile communication care app, which can seamlessly work with an existing EHR platform. The company expanded its product portfolio with this. , In May 2022, CPSI entered into a partnership agreement with Medicomp Systems to launch Quippe Clinical Lens. The new technology aims to empower EHR users with proper access to clinical information at PoC. .

Snapshot img

Renal Anemia Therapeutics Market Size 2025-2029

The renal anemia therapeutics market size is forecast to increase by USD 3.36 billion, at a CAGR of 9% between 2024 and 2029.

The market is driven by the substantial patient population suffering from Chronic Kidney Disease (CKD), making it a significant market with immense growth potential. This large patient base necessitates continuous development of effective treatments for managing renal anemia. Pharmacodynamic profiles are being optimized to minimize adverse events, while drug delivery systems are being developed to enhance patient compliance through convenient dosage regimens and administration methods. Another key trend in the market is the increasing adoption of biosimilars, which offer cost-effective alternatives to branded therapies, thereby expanding market access and affordability. However, the side-effects associated with the oral administration of renal anemia drugs pose a significant challenge to market growth.
These side-effects, including gastrointestinal disturbances and potential cardiovascular risks, necessitate the exploration of alternative delivery methods and the development of safer, more effective treatments. Companies seeking to capitalize on market opportunities should focus on addressing these challenges through innovative product development and strategic partnerships, ensuring they stay competitive in this dynamic market landscape. Genetic testing plays a crucial role in personalized medicine, allowing for precision dosing and improved patient outcomes.

What will be the Size of the Renal Anemia Therapeutics Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market is experiencing significant activity and trends, driven by the biopharmaceutical industry's continuous efforts to develop effective treatment options for this debilitating condition. Licensing agreements have been a prominent feature in the market, enabling collaborations between companies and research institutions to advance innovation. Marketing and sales strategies are evolving to address health disparities and improve healthcare utilization for patients with renal anemia. Future trends include a focus on patient outcomes, intellectual property protection, and health economics. Anemia management remains a priority in long-term care settings, with patient advocacy groups pushing for greater health equity and disease progression monitoring.
Public health initiatives aim to reduce healthcare costs by improving access to affordable treatments and optimizing care delivery. The global health community recognizes the importance of addressing renal anemia to improve patient quality of life and overall healthcare outcomes. The market is also driven by the increasing adoption of biosimilars, which offer cost-effective alternatives to branded drugs.

How is this Renal Anemia Therapeutics Industry segmented?

The renal anemia therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Type

  IV
  Oral


Distribution Channel

  Hospital pharmacy
  Retail pharmacy
  Online pharmacy


Form Factor

  Solid
  Liquid


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan


  South America

    Brazil


  Rest of World (ROW)

By Type Insights

The IV segment is estimated to witness significant growth during the forecast period. The market is witnessing significant growth, driven by the increasing prevalence of chronic kidney disease and the need for effective treatments to manage associated anemia. Overall, the market is expected to experience steady growth In the coming years, driven by the increasing prevalence of CKD and the availability of cost-effective treatment options. Erythropoiesis-stimulating agents (ESAs) remain a cornerstone of therapy, improving hemoglobin levels and enhancing quality of life for patients. However, challenges such as drug resistance, drug interactions, and adverse events necessitate ongoing research and development.

Phase III trials are underway for novel therapies, including gene therapy, stem cell therapy, and targeted drug delivery. Animal models are used extensively in preclinical studies to evaluate drug efficacy, metabolism, and safety. Regulatory approvals, such as EMA approval, are essential for market access and reimbursement policies. Drug formulation and stability are critical considerations for drug development, with intravenous (IV) administration remaining a popular choice due to its high therapeutic index and rapid onset of action. I